60132 Federal Register / Vol. 75, No. 188 / Wednesday, September 29, 2010 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Scientific Management Review Board. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Office of AIDS 

Research Advisory Council. 

Date: November 9, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: The theme of the meeting will be 

‘‘HIV/AIDS and Adolescents.’’ The meeting 

will focus on research to address: The 

epidemiology of HIV infection among 

adolescents; HIV prevention, treatment and 

care for adolescents; biological and cognitive 

development of HIV-infected adolescents; 

and ethical and regulatory issues for 

involving youth in AIDS clinical research. 

An update also will be provided on the 

OARAC Working Groups for HIV Treatment 

and Prevention Guidelines. 

Place: National Institutes of Health, 5635 

Fishers Lane, Terrace Level, Rockville, MD 

20852. 

Contact Person: Robert Eisinger, PhD, 

Executive Secretary, Director Of Scientific 

And Program Operations, Therapeutics 

Coordinating Committee, Office of AIDS 

Research, 5635 Fishers Lane, Msc 9310, Suite 

400, Rockville, MD 20852, (301) 496–0357, 

be4y@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.oar.nih.gov, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: September 22, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–24405 Filed 9–28–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group. 

Date: October 14–16, 2010. 

Time: 11 a.m. to 12 p.m. 

Agenda: Director’s Update; Emerging 

Opportunities in Gen and Target-Based 

Research in the NCI Intramural Program; 

Expert Panel and Board Discussion on the 

Implications of Gene and Target-Based 

Research Approaches in the Research 

Paradigm. 

Place: National Institutes of Health, 

Building 60, 1 Cloister Court, Room 142, 

Bethesda, MD 20814. 

Contact Person: Benjamin Carollo, MPA, 

Advocacy Relations Manager, Office of 

Advocacy Relations, Building 31, Room 

10A30, 31 Center Drive, MSC 2580, National 

Cancer Institute, NIH, DHHS, Bethesda, MD 

20892–2580, 301–496–0307, 

carollob@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 22, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–24413 Filed 9–28–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2) notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

preclinical development resources for 

potential new therapeutics for the 

treatment of cancer. The outcome of the 

evaluation will provide information to 

internal NCI committees that will 

decide whether NCI should support 

requests and make available contract 

resources for development of the 

potential therapeutic to improve the 

treatment of various forms of cancer. 

The research proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material and 

personal information concerning 

individuals associated with the 

proposed research projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Experimental Therapeutics Program (NExT). 

Date: October 7, 2010. 

Time: 8:30 a.m.–4:30 p.m. 

Agenda: To evaluate the NCI Experimental 

Therapeutics Program Portfolio. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Dr. Barbara Mroczkowski, 

Executive Secretary, NCI Experimental 

Therapeutics Program, National Cancer 

Institute, NIH, 31 Center Drive, Room 3A44, 


erowe on DSK5CLS3C1PROD with NOTICES